332 related articles for article (PubMed ID: 16531229)
1. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
Groll M; Berkers CR; Ploegh HL; Ovaa H
Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
[TBL] [Abstract][Full Text] [Related]
2. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
3. Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.
Purandare AV; Wan H; Laing N; Benbatoul K; Vaccaro W; Poss MA
Bioorg Med Chem Lett; 2004 Sep; 14(18):4701-4. PubMed ID: 15324891
[TBL] [Abstract][Full Text] [Related]
4. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
Pekol T; Daniels JS; Labutti J; Parsons I; Nix D; Baronas E; Hsieh F; Gan LS; Miwa G
Drug Metab Dispos; 2005 Jun; 33(6):771-7. PubMed ID: 15764713
[TBL] [Abstract][Full Text] [Related]
5. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Dick LR; Fleming PE
Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Mitsiades CS
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
[TBL] [Abstract][Full Text] [Related]
9. Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction.
Labutti J; Parsons I; Huang R; Miwa G; Gan LS; Daniels JS
Chem Res Toxicol; 2006 Apr; 19(4):539-46. PubMed ID: 16608165
[TBL] [Abstract][Full Text] [Related]
10. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
Fennell DA; Chacko A; Mutti L
Oncogene; 2008 Feb; 27(9):1189-97. PubMed ID: 17828309
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
12. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
Marx C; Yau C; Banwait S; Zhou Y; Scott GK; Hann B; Park JW; Benz CC
Mol Pharmacol; 2007 Jun; 71(6):1525-34. PubMed ID: 17392524
[TBL] [Abstract][Full Text] [Related]
13. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors.
Sprangers R; Li X; Mao X; Rubinstein JL; Schimmer AD; Kay LE
Biochemistry; 2008 Jul; 47(26):6727-34. PubMed ID: 18540636
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Dorsey BD; Iqbal M; Chatterjee S; Menta E; Bernardini R; Bernareggi A; Cassarà PG; D'Arasmo G; Ferretti E; De Munari S; Oliva A; Pezzoni G; Allievi C; Strepponi I; Ruggeri B; Ator MA; Williams M; Mallamo JP
J Med Chem; 2008 Feb; 51(4):1068-72. PubMed ID: 18247547
[TBL] [Abstract][Full Text] [Related]
15. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Arastu-Kapur S; Anderl JL; Kraus M; Parlati F; Shenk KD; Lee SJ; Muchamuel T; Bennett MK; Driessen C; Ball AJ; Kirk CJ
Clin Cancer Res; 2011 May; 17(9):2734-43. PubMed ID: 21364033
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
Basler M; Lauer C; Beck U; Groettrup M
J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
[TBL] [Abstract][Full Text] [Related]
18. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
19. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
20. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
